TCRR - TCR2 Therapeutics provides 2021 data and regulatory milestones

Clinical-stage immunotherapy company TCR2 Therapeutics (TCRR) lays out clinical data and regulatory milestones for the year, and predicts development of three product candidates in to clinical trials in 2021.Data from its phase-1 Gavo-cel study testing TRuC-T cell targeting mesothelin-positive non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma, is expected in H1 2021. Initiation of Phase 2 expansion cohort for the study is also anticipated in 2021.Plans to file an IND for a third TRuC-T cell program in 2021. Preclinical data from the allogeneic TRuC-T cell targeting mesothelin-positive solid tumors expected this year.TCR2 ended Q3 2020 with $246.7M in cash, cash equivalents, and investments.

For further details see:

TCR2 Therapeutics provides 2021 data and regulatory milestones